Pharmacological Effects of Crushing Prasugrel in STEMI Patients
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Prasugrel has shown to be superior to clopidogrel, in adjunct to aspirin, in preventing
recurrent ischemic events. Prasugrel is approved in patients with ST-elevation myocardial
infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) at a dosage of
60 mg loading dose (LD) followed by 10 mg/day. However, a delay in the onset of its
antiplatelet effects in this particular setting has been consistently shown. administration
of clopidogrel and ticagrelor crushed tablets has been tested and a faster and greater
bioavailability compared to the whole tablets has been observed. However, if the
administration of a crushed prasugrel LD may overcome the above limitation is still unknown
and represents the aim of our study. The proposed investigation will have a prospective,
randomized, design in which STEMI patients undergoing primary PCI will be randomized to
receive two different formulation of prasugrel LD (60 mg whole tablets and 60 mg crushed
tablets). Pharmacodynamic testing will be performed at several time points to test our study
hypothesis that crushed LD regiment will achieve more prompt and enhanced platelet inhibitory
effects.